138 completed, 99 recruiting, 47 unknown, 32 not yet recruiting. 91 Phase 3, 70 Phase 2, 56 Not applicable, 39 Phase 1, 12 Early Phase 1.
Follow Paraneoplastic Syndromes, Nervous System: new trials by email Literature Review of Paraneoplastic Syndromes, Nervous System trials Research Report on Paraneoplastic Syndromes, Nervous System
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG Myasthenia Gravis Generalized | Not yet recruiting | BioSensics | 25 | 2027-03-15 | 2026-10-13 | |
| Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) HN2301 injection - Generalized Myasthenia Gravis | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 6 | 2026-12-31 | 2026-08-12 |
| A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) Ublituximab, Placebo - Myasthenia Gravis | Phase 2 | Recruiting | TG Therapeutics, Inc. | 120 | 2026-10-01 | 2026-09-22 |
| Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies Autoimmune Encephalitis, Anti-NMDAR Encephalitis | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 300 | 2026-10-01 | 2026-10-05 | |
| Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis Myasthenia Gravis, Thymoma | Not yet recruiting | Assiut University | 30 | 2026-10-01 | 2026-10-01 | |
| A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab - Ocular Myasthenia Gravis | Phase 3 | Recruiting | UCB Biopharma SRL | 100 | 2026-09-16 | 2026-10-08 |
| Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma | Not yet recruiting | IRCCS San Raffaele | 40 | 2026-09-15 | 2026-05-06 | |
| An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis EA5 - Generalized Myasthenia Gravis (gMG) | Phase 1 | Not yet recruiting | Shanghai Lanyi Therapeutics Co., Ltd. | 18 | 2026-09-15 | 2026-09-14 |
| Pattern of AFP in Chhidren Admitted at Sohag University Hospital Observitional follow-up - Acute Flaccid Paralysis, AFP | Not yet recruiting | Mohamed Aboelhamd Ali | 30 | 2026-09-01 | 2026-09-11 | |
| A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis SHR-2173 injection, Placebo - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 60 | 2026-08-28 | 2026-10-22 |
| Feasibility of Remote Monitoring of Patients With Myasthenia Gravis Myasthenia Gravis (MG) | Recruiting | George Washington University | 18 | 2026-08-19 | 2026-10-05 | |
| Sexual and Urinary Dysfunctions in Generalized Myasthenia No intervetion - Myasthenia Gravis (MG) | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 150 | 2026-07-30 | 2026-07-01 | |
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2026-07-27 | 2026-10-21 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Inebilizumab - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Amgen | 15 | 2026-07-21 | 2026-10-05 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-10-16 |
| Universal STAR-T Cell Injection in Generalized Myasthenia Gravis Universal STAR-T Cell - Generalized Myasthenia Gravis | Phase 1 | Not yet recruiting | Daishi Tian | 10 | 2026-07-06 | 2026-07-20 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Claseprubart, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Recruiting | Dianthus Therapeutics | 195 | 2026-06-29 | 2026-09-25 |
| Efgartigimod in Anti-NMDA Receptor Encephalitis. Efgartigimod Alfa - Encephalitis Autoimmune | Phase 2 | Recruiting | Beijing Tongren Hospital | 20 | 2026-06-25 | 2026-09-16 |
| Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab) Patients diagnosed with generalized myasthenia gravis and treated with Rozanolixizumab - Generalized Myasthenia Gravis | Recruiting | Centre Hospitalier Universitaire de Nice | 50 | 2026-06-15 | 2026-09-01 |
Showing 20 of 388. Sign in to see all of them.
Myasthenia Gravis (319) · Multiple Sclerosis (35) · Myelitis, Transverse (32) · Neuromyelitis Optica (32) · Autoimmune Diseases of the Nervous System (27) · Lambert-Eaton Myasthenic Syndrome (22) · Autoimmune Diseases (21) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (15) · Anti-N-Methyl-D-Aspartate Receptor Encephalitis (13) · Guillain-Barre Syndrome (12) · Neuromuscular Diseases (11) · Optic Neuritis (10) · Recurrence (10) · Thymoma (10) · Fatigue (9)
Neoplasms by Site (388) · Nervous System Neoplasms (388) · Neurodegenerative Diseases (388) · Neoplasms (386) · Paraneoplastic Syndromes (386) · Nervous System Diseases (381) · Immune System Diseases (378) · Autoimmune Diseases (360) · Autoimmune Diseases of the Nervous System (353) · Neuromuscular Junction Diseases (329) · Neuromuscular Diseases (327) · Pathological Conditions, Signs and Symptoms (77) · Central Nervous System Diseases (75) · Demyelinating Diseases (65)
Amifampridine (13) · Rituximab (12) · efgartigimod alfa (11) · rozanolixizumab (11) · Cyclophosphamide (9) · Prednisone (8) · eculizumab (8) · ravulizumab (8) · zilucoplan (8) · Immunoglobulins, Intravenous (7) · Pyridostigmine Bromide (7) · Mycophenolic Acid (6) · Tacrolimus (6) · fludarabine (6) · telitacicept (6)
Alexion Pharmaceuticals, Inc. (20) · argenx (17) · UCB Biopharma SRL (14) · Charite University, Berlin, Germany (6) · Assistance Publique - Hôpitaux de Paris (5) · Catalyst Pharmaceuticals, Inc. (5) · Centre Hospitalier Universitaire de Nice (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (5) · Huashan Hospital (5) · Leiden University Medical Center (5) · Tang-Du Hospital (5) · Tongji Hospital (5) · Assiut University (4) · Beijing Tongren Hospital (4) · Da, Yuwei, M.D. (4)
United States (180) · China (91) · Italy (69) · Canada (63) · Germany (61) · France (59) · Spain (56) · Poland (55) · United Kingdom (48) · Japan (45) · Belgium (32) · Denmark (29) · Netherlands (27) · Taiwan (24) · Serbia (23)
Andreas Meisel, Prof. Dr. med. (3) · Benjamin Greenberg, MD (3) · Raffaele Iorio (3) · Antonio Guglietta, MD (2) · Chongbo Zhao (2) · Daishi Tian (2) · David Richman, MD (2) · Donald Sanders, MD (2) · Gil Wolfe, MD (2)
PMID 37059507, PMID 42388397, PMID 21211990, PMID 30905021, PMID 32189108, PMID 32426038, PMID 32700461, PMID 33219142, PMID 33229455, PMID 33329303, PMID 33676197, PMID 34146511, PMID 34498507, PMID 34590717, PMID 35350948, PMID 37059508, PMID 38099334, PMID 38400914, PMID 39068745, PMID 39314260, PMID 40105996, PMID 40504283, PMID 42855714, PMID 10227640, PMID 10625901, PMID 10891897, PMID 11339776, PMID 11383846, PMID 11459743, PMID 12236201, PMID 12691631, PMID 16267188, PMID 16831964, PMID 16849828, PMID 16900450, PMID 17264722, PMID 18173374, PMID 18256991, PMID 18567886, PMID 18675464, PMID 18946293, PMID 19252779, PMID 197596, PMID 19838774, PMID 20035902, PMID 20117014, PMID 20375901, PMID 20606544, PMID 20683334, PMID 20818891
2023 (11), 2025 (9), 2019 (6), 2018 (5), 2016 (4), U54NS115054 (2), 1RC3NS070670-01 (1), 2014 (1), 2015 (1), 2017 (1), R01EY029437 (1), R44NS122672 (1), U01NS042685 (1), U01NS077179 (1), U01NS077352 (1)